The renoprotective effects of canagliflozin demonstrated in the CREDENCE study cannot yet be considered as an effect of the whole class of SGLT2 inhibitors

Abstract

Summary with commentary. Citation: Schernthaner G, Groop PH, Kalra PA, et al.

SGLT-2 inhibitor renal outcome modification in type-2 diabetes: Evidence from studies in patients with high or low renal risk. Diabetes Obes Metab. 2020 Jul; 22 (7): 1024-1034.

Keywords

• canagliflozin
• CREDENCE study
• SGLT2 inhibitors